Assistance Programs, Dividends, Campaigns, Drug Recommendations, and Research Collaborations - Research Reports on Duke Energy, Exelon, Marriott, Vertex and AstraZeneca

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 27, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Duke Energy Corporation (NYSE: DUK), Exelon Corporation (NYSE: EXC), Marriott International, Inc. (NASDAQ: MAR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and AstraZeneca PLC (NYSE: AZN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7439-100free.

--
Duke Energy Corporation Research Reports
On October 21, 2014, Duke Energy Corporation (Duke Energy) announced the launch of its assistance program, Helping Home Fund, a $20 million program authorized through an agreement with the N.C. Public Staff and approved by the N.C. Utilities Commission during the 2013 Duke Energy Progress and Duke Energy Carolinas rate cases. Under the program, Duke Energy Progress and Duke Energy Carolinas will distribute $10 million each. The program will provide income-qualified customers with up to $10,000 in energy efficiency upgrades at no cost to the customer. The Company informed that program funds will come from Duke Energy shareholders, and not through customer rates. Paul Newton, Duke Energy State President - North Carolina, commented, "These funds will provide energy-saving measures at no charge to customers who may not otherwise be able to afford them. Duke Energy's Helping Home Fund will bring real help to our customers, and real benefits for years to come." The full research reports on Duke Energy are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/DUK/report.pdf

--
Exelon Corporation Research Reports
On October 21, 2014, Exelon Corporation (Exelon) reported that its Board has declared a $0.31 per share of regular quarterly dividend on the Company's common stock. Exelon informed that the dividend is payable on December 10, 2014, to shareholders of record of Exelon as of 5:00 p.m. New York Time on November 14, 2014. The full research reports on Exelon are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/EXC/report.pdf

--
Marriott International, Inc. Research Reports
On October 21, 2014, Marriott International, Inc. (Marriott) reported that the Company has recently launched "Great Bed, Great Cause," a ShopMarriott campaign which will be active through November 7, 2014. Under the campaign, ShopMarriott (the official retailer of Marriott Hotels) will donate a bed for every bed purchased to Good360, an international nonprofit organization. The Company added that through Good360, the new Marriott beds will be donated to organizations that help individuals and families in need of a bed. Marriott's Erin Butler, Spa and Retail Analytics Manager said, "Our partnership with Good360 demonstrates our ongoing commitment to investing in the communities where we do business." The full research reports on Marriott are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/MAR/report.pdf

--
Vertex Pharmaceuticals Incorporated Research Reports
On October 21, 2014, Vertex Pharmaceuticals Incorporated (Vertex) announced that it has received the U.S. Food and Drug Administration's (FDA) Pulmonary Allergy Drugs Advisory Committee's approval for KALYDECO® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene, which is the indication being reviewed by the FDA. The Company informed that the FDA is expected to decide on the approval of ivacaftor by December 30, 2014 under the Prescription Drug User Fee Act. Jeffrey Chodakewitz, M.D., Senior Vice President and Chief Medical Officer at Vertex stated, "Today's recommendation is a positive and important step toward making ivacaftor available for people ages 6 and older with the R117H mutation." The full research reports on Vertex are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/VRTX/report.pdf

--
AstraZeneca PLC Research Reports
On October 16, 2014, AstraZeneca PLC (AstraZeneca) and its global biologics research and development arm, MedImmune, announced that building on their existing partnership with the University of Cambridge, they have entered into four new collaborations with the University. The collaborations cover the following areas: advancement of research and development in neurodegenerative diseases; access to researchers from the University of Cambridge to key compounds from AstraZeneca's pipeline for investigation; a PhD programme to support future leaders in science; and an entrepreneur-in-residence programme. Commenting on the partnership, Mene Pangalos, Executive Vice President of Innovative Medicines & Early Development, AstraZeneca said, "These new agreements will not only bring our teams closer to the world-class academic investigators at the University of Cambridge, but will also enable us to actively support the development of the next generation of leading scientists right here in the UK." The full research reports on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/Oct-27-2014/AZN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

 

SOURCE Analysts Review

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…